SOCIAL ISSUES ASSOCIATED WITH OBESITY
SOCIAL ISSUES ASSOCIATED WITH OBESITY
SOCIAL ISSUES ASSOCIATED WITH OBESITY
Anyone who has watched an episode of Friends or The OC has seen the glorified ideal of being thin; the characters are extremely thin and ultimately many people who watch the show are inclined to want to lose weight, even if they do so [...]
Dietary Supplements stimulants for Weight Loss
Dietary Supplements stimulants for Weight Loss
With the withdrawal of ephedra from the U.S. market, companies producing dietary supplements for weight loss have replaced ephedra with other stimulants to induce weight loss. Many of these stimulants contain caffeine or are very similar to caffeine. Caffeine and related substances suppress appetite and cause increased [...]
Copies of Diet Drug Acomplia (Rimonabant)
Copies of diet drug Acomplia ( rimonabant ) are being widely sold at Indian pharmacies without a prescription for as little as $3.60 for a month’s supply of the pill, according to reports from the Indian media.
A half-dozen pharmaceutical companies — including such well-regarded generic drug manufacturers [...]
Study: Highly Encouraging Two-Year Trial Results Reported for Acomplia
The new diet drug rimonabant (Acomplia) helped people lose significantly more weight than a placebo in a two-year clinical trial, the largest of the studies of this drug conducted to date, according to researchers.
The study also showed that while most Acomplia (rimonabant) [...]
Is No News Good News for Acomplia
In the past month, the new anti–obesity drug Acomplia (rimonabant) has virtually disappeared from the news, leading a number of the millions of overweight men Acomplia (rimonabant) and women who had been hoping it might be available before the end of the year to wonder what’s going on.
Well, what [...]
Study: Acomplia Produces Weight Loss and Metabolic Improvement
Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new Acomplia (rimonabant) class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia [...]
Report: Many Seek Accomplia, But the Hype Exceeds What Is Known So Far
At obesity treatment centers, nearly every Acomplia (rimonabant) patient now asks for Acomplia (rimonabant), the New York Times reports. But many medical researchers, the newspaper found, say that while rimonabant may be intriguing, “the mythology in the making is hardly justified by what is known so far. [...]
New “News” — Well, Not Exactly — About Benefits of Acomplia
A new report in the prestigious New Acomplia (rimonabant) England Journal of Medicine has focused renewed attention on one of the earlier studies of Acomplia (rimonabant) — originally reported on in March 2004 — which found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost [...]
